GLOW and Wolverine: what changes?
GLOW is listed with three components: GHK 50 mg, BPC 10 mg and TB 10 mg, totalling 70 mg. Wolverine lists BPC 10 mg and TB 10 mg, totalling 20 mg. The source-listed BPC and TB amounts are the same in both entries; the GHK component accounts for the additional 50 mg in GLOW.
This is a composition comparison. It does not establish which formulation is appropriate for a particular experiment or whether combining its materials changes their behaviour. Ask for component identity and quantitative results for the whole blend.
KLOW: confirm the current formulation
The KLOW entry remains “Specification on request”. Ask for the complete verified component sheet before comparing it with another blend. The selected batch record should identify every material, its amount and the reconciled total.
Ipamorelin + CJC without DAC: define the pairing
For an Ipamorelin + CJC (no DAC) enquiry, request the exact sequence of the CJC-related material, the amount of each component, the combined total and the ratio. Match the trade expression “without DAC” to the molecular specification and ask for the corresponding quantitative batch results.
How individual research profiles fit the comparison
Published research helps explain the scientific questions associated with individual compounds. It is separate from evidence about a finished combination.
- GHK-Cu: fibroblast and extracellular-matrix biology, including a primary cell-culture study.
- BPC-157: preclinical tissue-response research; a rat tendon-fibroblast study investigated growth-hormone-receptor expression.
- TB-500: a thymosin-beta-4-related name for which the sequence matters. Analytical research examined an N-acetylated LKKTETQ fragment.
- KPV: inflammatory-signalling research, with primary work in cell systems and mouse models.
These references do not test the Aurelis blends. Evidence for an individual material cannot by itself establish blend stability, synergy or clinical performance.
What to ask for when comparing blend documentation
- Full identity: the complete name or sequence of every component, rather than the blend's trade name alone.
- Defined amounts: each component's content and the combined total, with an explanation of any discrepancy.
- Batch traceability: the lot identifier, sample details, report date and issuer.
- Analytical methods: component-specific identity and quantitative results, alongside any chromatographic purity profile.
- Formulation information: the presentation, relevant excipients, storage and applicable stability data.
A single purity percentage does not necessarily establish the content of every ingredient. Use the quality and documentation guide when reviewing a blend record.
Single compound or combination presentation?
Single-compound entries let an enquiry identify one material and one listed strength. A combination adds composition and analytical questions. Define the research question and the specification needed before choosing a presentation; the catalogue name does not replace that review.
For local availability in Australia, Canada or the USA, send the blend name, required formulation, destination and document requirements through our enquiry page. Our team confirms the specification and local stock before supply is agreed.
Research context and catalogue comparison reviewed 30 September 2026.